Evrysdi vs Spinraza
Side-by-side cost comparison based on Medicare Part D data
Evrysdi
Risdiplam
Manufactured by Genentech/Roche
Spinraza
Nusinersen
Manufactured by Biogen
Evrysdi costs 57% less per claim than Spinraza ($31,500.00 vs $73,000.00). A generic version of Evrysdi is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Evrysdi | Spinraza |
|---|---|---|
| Avg Cost Per Claim | $31,500.00 | $73,000.00 |
| Total Medicare Spending | $567.0M | $876.0M |
| Total Beneficiaries | 3,600 | 2,400 |
| Total Claims | 18,000 | 12,000 |
| Annual Cost/Patient | $157,500.00 | $365,000.00 |
| Year-over-Year Change | +42.6% | -14.2% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Genentech/Roche | Biogen |
| Condition | Rare Diseases | Rare Diseases |
| Generic Name | Risdiplam | Nusinersen |
Evrysdi vs Spinraza: What the Data Shows
Evrysdi (Risdiplam) and Spinraza (Nusinersen) are both used to treat rare diseases. Based on Medicare Part D data, Evrysdi costs $31,500.00 per claim, which is 57% less than Spinraza at $73,000.00 per claim.
Medicare spent $567.0M on Evrysdi and $876.0M on Spinraza. In terms of patient reach, Evrysdi serves more beneficiaries (3,600 vs 2,400).
Year-over-year spending changed +42.6% for Evrysdi and -14.2% for Spinraza. Evrysdi saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Evrysdi is cheaper at $31,500.00 per claim, compared to $73,000.00 for Spinraza. That makes Evrysdi about 57% less expensive per claim based on Medicare Part D data.
Yes, both Evrysdi and Spinraza are used to treat rare diseases. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Risdiplam and generic Nusinersen can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $567.0M on Evrysdi covering 3,600 beneficiaries, and $876.0M on Spinraza covering 2,400 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.